Par Pharmaceutical, Inc. d/b/a Par Pharmaceutical, Par Pharmaceutical Companies, Inc. | Search

Accessibility help Skip to navigation Skip to content Skip to footer

Showing results for Par Pharmaceutical, Inc. d/b/a Par Pharmaceutical, Par Pharmaceutical Companies, Inc.

Sort by

Viewing results 1‒25 of 74

News in-depthDrug prices
Drugmakers demand big cut in Britain’s medicines levy
...Pharmaceutical companies have fired the opening shots in a battle with the UK’s NHS over a de facto drugs tax they pay the government, warning that Britain could miss out on £6bn of research and development...
February 27, 2023
The Big Read
The inside story of the Pfizer vaccine: ‘a once-in-an-epoch windfall’
...Fatima Hassan, founder of South Africa’s Health Justice Initiative, says the health ministry was ill-equipped to negotiate with a “lawyered-up” pharmaceutical company like Pfizer....
November 30, 2021
FT Live
US Pharma and Biotech Summit
Strategies for innovation, pricing and access
Thursday, 16 MayNew York, NY, USA
Covid-19 vaccines
Scientists probe impact on vaccines of Covid variant found in India
...That put B.1.617.1 “on a par” with the variant first identified in South Africa, which has been found to reduce the efficacy of some shots, Suthar said....
May 12, 2021
The FT ViewThe editorial board
Vaccine protectionism by the EU will backfire
...There is a suspicion that pharmaceutical companies are using EU facilities to fulfil priority international orders while EU customers have to wait....
January 26, 2021
Covid-19 vaccines
Iran’s vaccination drive becomes ensnared in geopolitics
...Iran’s pharmaceutical industry has a long history of producing vaccines for diseases such as polio, hepatitis B, measles, tetanus, diphtheria and rubella, though it still relies on imports for human papillomavirus...
February 11, 2021
News in-depthCoronavirus treatment
How AstraZeneca and Oxford found their vaccine under fire
...“We can definitely say that the transparency from Oxford and AstraZeneca has not been on a par with what we have seen from the others,” said Rasmus Bech Hansen, chief executive of Airfinity, a London-based...
November 27, 2020
FT Live
Global Private Banking Awards 2024
Celebrating excellence in wealth management
Thursday, 7 NovemberThe Landmark London, London, UK
#techAsia
Sony chief: mobility is the next megatrend
...RWDC Industries, a Singapore-based biotech start-up, has raised $133m in a Series B round led by Vickers Venture Partners, Flint Hills Resources (the energy and resources company) and CPV/CAP Pensionskasse...
May 6, 2020
Health
FT Health: Time to reclassify tobacco?
...News round-up Drugmakers and prices The World Health Assembly agreed to push for more transparency on drug pricing, but was criticised for not making pharma companies reveal their R&D costs....
May 31, 2019
Equities
Markets Now - Tuesday 17th March 2020
...We believe oil use is now down 8m b/d, coffee down c.10% and even gold sales to EM CBs are down....
March 17, 2020
Technology sector
Big hedge fund bet on NXP hit by trade war
...Buried within bond contracts are clauses that have enabled some large companies to buy back debt issued to finance deals at par and thus not pay a premium....
July 20, 2018
FT AlphavilleIPOs
Guess the company, Howard Marks edition
...Next up:Over the past two years, company D has spent an amount on buybacks equal to 85% of a year’s ebitda....
October 2, 2018
Pharmaceuticals sector
Indivior warns of threat to key opioid addiction treatment after legal setback
...Watson Pharmaceuticals and Par Pharmaceutical have previously been prevented from working on a generic film alternative, but Indivior said the latest ruling means they “are now able to pursue their respective...
September 1, 2017
FT AlphavilleSiona Jenkins
Opening Quote: Indivior suffers legal setback on opioid treatment
...Watson Pharmaceuticals and Par Pharmaceutical have previously been prevented from working on a generic film alternative, but Indivior said the latest ruling means they “are now able to pursue their respective...
September 1, 2017
News in-depthUS & Canadian companies
MAmazon makes its move in healthcare
...have vested interests on a par with the Caribbean dictatorship....
January 31, 2018
Pharmaceuticals sector
Mylan drops as AGs look to expand generic drug-pricing lawsuit
...Reddy’s Laboratories, Inc.; Emcure Pharmaceuticals, Ltd.; Glenmark Pharmaceuticals, Inc.; Lannett Company, Inc.; Par Pharmaceutical Companies, Inc.; Sandoz, Inc.; Sun Pharmaceutical Industries,Inc.; and...
October 31, 2017
FT Live
Global Pharma and Biotech Summit
Driving life sciences innovation in a disrupted world
Tuesday, 5 NovemberIn-Person & Online Conference
FT AlphavilleDavid Keohane
Further reading
...– Insider trading par du jour: “Mr. Walters was said to have provided a cellphone, called the Bat Phone, to Mr....
April 6, 2017
US equities
Drugmaker Endo rises on leadership change
...Mr Campanelli previously served as chief executive of Par Pharmaceutical and joined Endo after the company bought Par in 2015....
September 23, 2016
UK banks
Week in Review: January 28
...The company also helped to assuage investor fears over the margins of its newer growth businesses, by disclosing a commercial cloud gross margin of 48 per cent — on par with the previous quarter....
January 27, 2017
UK equities
Supermarkets in retreat on Asda war signal
...While generic drugmakers Actavis and Par are expected to appeal against the verdict, Indivior will now have at least another year to launch its successor treatment, a monthly injection, said Deutsche Bank...
June 3, 2016
High yield bonds
Healthcare junk bonds sting investors
...Dealmakers have struck $460bn in M&A transactions in healthcare since the year began, including Valeant’s $15.8bn deal for Salix, as well as Endo’s purchase of Par Pharmaceutical from TPG Capital and Mallinckrodt...
October 1, 2015
LexUS & Canadian companies
Endo/Par: too much of a good thing
...Why, then, is the market so tepid on Endo’s $8bn cash and stock purchase of Par, a generics company? After Monday’s announcement, Endo’s shares fell 5 per cent....
May 18, 2015
US & Canadian companies
Endo to buy Par from TPG Capital in $8bn cash-and-shares deal
...The deal is the latest in a feverish game of brinkmanship being played out by some of the biggest companies in the pharmaceuticals sector....
May 18, 2015
Oil
Welcome to the new oil order
...On paper the US might produce 9.3m barrels a day against Russia’s 11.1m b/d and Saudi Arabia’s 10.3m b/d....
January 28, 2016
Pharmaceuticals sector
Australia’s CSL warns of biotech bubble
...This has coincided with a wave of M&A activity in the pharmaceutical and healthcare sector, including Shire’s US$30bn hostile takeover approach last week to US drugmaker Baxalta — a key competitor of CSL...
August 10, 2015
US equities
Ann leaps after Ascena declares intentions
...The deal would help create a pharmaceutical company with a fast-growing generics business and it is also expected to drive long-term double-digit sales growth, according to Endo....
May 18, 2015

Previous pagePage 1 of 3Next page